Second Cancers After Myeloma Stem Cell Transplant: What Is the Long-Term Risk? | IMS 2026

Damian Mikulski, MD, PhD, of the Medical University of Lodz discusses second cancers after autologous stem cell transplant at IMS 2026 in Glasgow. In a study with MD Anderson Cancer Center of about 2,400 patients treated in the modern era, about 10% developed a second cancer, sometimes more than 10 years after transplant. He explains which types appeared and when, which factors were linked to them, and how they affected survival. The key takeaway: long-term monitoring is essential.

Timestamps:

0:00 Introduction

0:21 Why second cancers matter

1:01 Who was studied

1:18 How common they are and which types

1:49 When they occur

2:04 What raised the risk

2:25 Survival and conclusions

If this video has helped you or a loved one, consider donating to HealthTree. Every donation helps us continue to create free and high-quality blood cancer educational content: https://give.healthtree.org/give/628617/src=htu

For an organized lesson structure, watch on our site here: https://linktr.ee/HealthTreeUniversity

Create a free account to track your progress, bookmark lessons, and keep up-to-date on the latest advancements in treating cancer!

Patients have the key to find cures for cancer. Learn more about HealthTree's services here: https://healthtree.org/curehub?utm_source=social+media&utm_medium=htu+youtube&utm_campaign=htu-curehub&utm_content=general

Educated and empowered patients have better outcomes. We've partnered with hundreds of medical experts and doctors to help you learn more about your disease.